Strong antibody response after a first dose of a SARS‐CoV‐2 mRNA‐based vaccine in kidney transplant recipients with a previous history of COVID‐19

Benotmane, Ilies; Gautier ‐Vargas, Gabriela; Gallais, Floriane; Gantner, Pierre; Cognard, Noëlle; Olagne, Jérôme; Velay, Aurélie; Heibel, Françoise; Braun‐Parvez, Laura; Martzloff, Jonas; Perrin, Peggy; Moulin, Bruno; Fafi‐Kremer, Samira; Caillard, Sophie

A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).1,2 While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,3-5 the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.